{"ATC Code":"G04BE03","Abbreviation":"Viagra","Aliases":["Aphrodil","Vizarsin","Patrex","Sildenafil teva","Sildenafil actavis","Sildenafilo","1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine","HIP0908","HIP-0908","5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one"],"Biological Half-Life":"The terminal phase half-life observed for sildenafil is approximately 3 to 5 hours.","CAS":"139755-83-2","ChEBI":"CHEBI:9139","ChEMBL":"CHEMBL192","ChemicalClasses":["ethylamine"],"Chirality":"achiral","Classes":null,"Color/Form":"Crystals","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Lower":42.5,"Upper":50},"Heavy":{"Lower":100,"Upper":100},"Light":{"Lower":1,"Upper":42.5},"Strong":{"Lower":50,"Upper":100},"Threshold":{"Lower":0.5,"Upper":1}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Cardiovascular Agents; Phosphodiesterase 5 Inhibitors; Urologic Agents; Vasodilator Agents","Drug Indication":"Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:  (1) the treatment of erectile dysfunction; and  (2) treatment of pulmonary hypertension, where: a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%);  b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy; and  c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.","Drug Warnings":"Administration of Viagra with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated. Consistent with its known effects on the nitric oxide/cGMP pathway, Viagra was shown to potentiate the hypotensive effects of nitrates.","DrugClasses":[],"DurationOfAction":"","EliminationHalfLife":"3–4 hours","Esters":["acetate"],"European Community (EC) Number":"604-158-7","FDA Pharmacological Classification":"3M7OB98Y7H","FullSalts":["Sildenafil citrate"],"HMDB ID":"HMDB0005039","HeavyAtomCount":33,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Cardiovascular Agents; Phosphodiesterase 5 Inhibitors; Urologic Agents; Vasodilator Agents","IUPACName":"5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one","InChI":"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)","InChIKey":"BNRNXUUZRGQAQC-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Compounds that specifically inhibit PHOSPHODIESTERASE 5. (See all compounds classified as Phosphodiesterase 5 Inhibitors.)","Melting Point":"189-190 °C","MolecularFormula":"C\u003csub\u003e22\u003c/sub\u003eH\u003csub\u003e30\u003c/sub\u003eN\u003csub\u003e6\u003c/sub\u003eO\u003csub\u003e4\u003c/sub\u003eS","MolecularWeight":"474.6 g/mol","Pharmacodynamics":"In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5). Its effect is more potent on PDE5 than on other known phosphodiesterases. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.  In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours.  Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg) . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen.  Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either.  In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (\u003e 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline. Mean pulmonary systolic blood pressure decreased by 9%. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries.  Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test).","Physical Description":"Solid","PrevSalts":["citrate"],"PubChemId":135398744,"Record Description":["Sildenafil is a pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. It has a role as a vasodilator agent and an EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor. It is a pyrazolopyrimidine, a member of piperazines and a sulfonamide.","In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5). The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid.  Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment for angina - or chest pain associated with inadequate blood flow to the heart - before being serendipitously indicated for treating erectile dysfunction in the late 1980s. Nevertheless, it is because of this mechanism that sildenafil is also indicated for treating pulmonary arterial hypertension but is also additionally notorious for interacting with various anti-anginal or anti-hypertensive agents to develop potentially rapid, excessive, and/or fatal hypotensive crises.  Regardless, sildenafil, among a variety of other similar or related PDE5 inhibitors, has become a common and effective treatment for erectile dysfunction and since its formal approval for medical use in the public in 1998, continues to see millions of prescriptions written for it internationally. Although the medication has historically been most popularly recognized as Pfizer's brand name Viagra, sildenafil is currently available generically and even as a non-prescription over the counter medication in some countries.","Sildenafil is a Phosphodiesterase 5 Inhibitor. The mechanism of action of sildenafil is as a Phosphodiesterase 5 Inhibitor.","Sildenafil functions as a selective and competitive inhibitor of type 5 phosphodiesterases (PDE5) on smooth muscle cells in the penis and pulmonary vasculature, and is used extensively for erectile dysfunction and less commonly for pulmonary hypertension. Sildenafil has been associated with rare instances of clinically apparent liver injury.","Sildenafil is an orally bioavailable pyrazolopyrimidinone derivative structurally related to zaprinast, with vasodilating and potential anti-inflammatory activities. Upon oral administration, sildenafil selectively targets and inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), thereby inhibiting the PDE5-mediated degradation of cGMP found in smooth muscle and increasing cGMP availability. This results in prolonged smooth muscle relaxation in the corpus cavernosum of the penis, thereby causing vasodilation, blood engorgement and a prolonged penile erection.  In the smooth muscle of the pulmonary vasculature, the increase in cGMP results in smooth muscle relaxation, vasodilation of the pulmonary vascular bed, relieving pulmonary hypertension and increasing blood flow in the lungs. In addition, sildenafil may reduce airway inflammation and mucus production.","SILDENAFIL is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 79 investigational indications.","A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.","See also: Sildenafil Citrate (has salt form); Sildenafil Nitrate (is active moiety of).","Sildenafil is a pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. It has a role as a vasodilator agent and an EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor. It is a pyrazolopyrimidine, a member of piperazines and a sulfonamide.","LiverTox|Urologic|Erectile Dysfunction|PDE-3 inhibitor"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Sildenafil","Name":"Sildenafil","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q191521","Name":"Sildenafil","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00203","Name":"Sildenafil","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/135398744","Name":"Sildenafil","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL192","Name":"Sildenafil","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9139","Name":"Sildenafil","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=139755-83-2","Name":"Sildenafil","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005039","Name":"Sildenafil","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07259","Name":"Sildenafil","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/3M7OB98Y7H","Name":"Sildenafil","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6023579","Name":"Sildenafil","Sub":false}]}],"SMILES":"CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C","Salts":["citrate"],"SaltsAcidCount":[0],"SaltsAmineCount":[1],"SaltsUNII":["BW9B0ZE037"],"Scheduling":[{"gov":"Australia","schedule":"S4 substance"},{"gov":"Canada","schedule":"prescription only substance"},{"gov":"United Kingdom","schedule":"P substance"},{"gov":"United States","schedule":"prescription only substance"},{"gov":"European Union","schedule":"prescription only substance"}],"Solubility":"White to off-white crystalline powder; solubility in water: 3.5 mg/mL /Sildenafil citrate/","Stability/Shelf Life":"Reconstituted sildenafil oral suspension is stable for 30 days when stored as directed; any remaining suspension should be discarded after that time.","StoreUNII":["3M7OB98Y7H"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="95.539mm" version="1.2" viewBox="0 0 172.881 95.539" width="172.881mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="96.0" stroke="none" width="173.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="1.001" x2="5.729" y1="77.982" y2="63.493"/>
                  
            <line class="bond" id="mol1bnd2" x1="5.729" x2="20.639" y1="63.493" y2="60.343"/>
                  
            <line class="bond" id="mol1bnd3" x1="20.639" x2="25.367" y1="60.343" y2="45.855"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="19.031" x2="25.367" y1="37.143" y2="45.855"/>
                        
                <line x1="21.003" x2="26.3" y1="35.709" y2="42.993"/>
                      
                <line class="hi" stroke="#3050F8" x1="19.031" x2="22.198999999999998" y1="37.143" y2="41.498999999999995"/>
                <line class="hi" stroke="#3050F8" x1="21.003" x2="23.6515" y1="35.709" y2="39.351"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="19.012" x2="22.781" y1="29.976" y2="24.751"/>
                  
            <line class="bond" id="mol1bnd6" x1="28.638" x2="39.895" y1="22.241" y2="25.941"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="39.895" x2="39.895" y1="25.941" y2="41.181"/>
                        
                <line x1="42.334" x2="42.334" y1="27.349" y2="39.778"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="25.367" x2="39.895" y1="45.855" y2="41.181"/>
                  
            <line class="bond" id="mol1bnd9" x1="39.895" x2="49.851" y1="41.181" y2="46.969"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="56.158" x2="66.311" y1="46.994" y2="41.181"/>
                        
                <line x1="54.946" x2="63.873" y1="44.878" y2="39.767"/>
                      
                <line class="hi" stroke="#3050F8" x1="56.158" x2="61.234500000000004" y1="46.994" y2="44.0875"/>
                <line class="hi" stroke="#3050F8" x1="54.946" x2="59.409499999999994" y1="44.878" y2="42.322500000000005"/>
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="66.311" x2="66.311" y1="41.181" y2="29.791"/>
                  
            <line class="bond" id="mol1bnd12" x1="63.158" x2="53.103" y1="24.122" y2="18.321"/>
                  
            <line class="bond" id="mol1bnd13" x1="39.895" x2="53.103" y1="25.941" y2="18.321"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="51.884" x2="51.884" y1="19.025" y2="7.002"/>
                        
                <line x1="54.323" x2="54.323" y1="19.025" y2="7.002"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="51.884" x2="51.884" y1="7.001999999999999" y2="13.013499999999999"/>
                <line class="hi" stroke="#FF0D0D" x1="54.323" x2="54.323" y1="7.001999999999999" y2="13.013499999999999"/>
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="66.311" x2="79.496" y1="41.181" y2="48.825"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="79.496" x2="79.471" y1="48.825" y2="64.074"/>
                        
                <line x1="81.932" x2="81.911" y1="50.237" y2="62.671"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="79.471" x2="92.659" y1="64.074" y2="71.728"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="92.659" x2="105.872" y1="71.728" y2="64.134"/>
                        
                <line x1="92.665" x2="103.436" y1="68.912" y2="62.722"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="105.872" x2="105.897" y1="64.134" y2="48.886"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="105.897" x2="92.709" y1="48.886" y2="41.231"/>
                        
                <line x1="103.456" x2="92.703" y1="50.288" y2="44.047"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="79.496" x2="92.709" y1="48.825" y2="41.231"/>
                  
            <line class="bond" id="mol1bnd22" x1="105.897" x2="116.366" y1="48.886" y2="42.869"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="115.837" x2="110.937" y1="39.276" y2="33.414"/>
                        
                <line x1="117.708" x2="112.808" y1="37.712" y2="31.85"/>
                      
                <line class="hi" stroke="#C6C62C" x1="115.837" x2="113.387" y1="39.276" y2="36.345"/>
                <line class="hi" stroke="#FF0D0D" x1="110.937" x2="113.387" y1="33.414" y2="36.345"/>
                <line class="hi" stroke="#C6C62C" x1="117.708" x2="115.25800000000001" y1="37.712" y2="34.781000000000006"/>
                <line class="hi" stroke="#FF0D0D" x1="112.808" x2="115.25800000000001" y1="31.85" y2="34.781000000000006"/>
            </g>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="120.531" x2="125.443" y1="37.713" y2="31.883"/>
                        
                <line x1="122.396" x2="127.308" y1="39.284" y2="33.454"/>
                      
                <line class="hi" stroke="#C6C62C" x1="120.531" x2="122.987" y1="37.713" y2="34.798"/>
                <line class="hi" stroke="#FF0D0D" x1="125.443" x2="122.987" y1="31.883" y2="34.798"/>
                <line class="hi" stroke="#C6C62C" x1="122.396" x2="124.852" y1="39.284" y2="36.369"/>
                <line class="hi" stroke="#FF0D0D" x1="127.308" x2="124.852" y1="33.454" y2="36.369"/>
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="121.866" x2="129.142" y1="42.89" y2="47.11"/>
                  
            <line class="bond" id="mol1bnd26" x1="132.285" x2="132.258" y1="52.788" y2="64.186"/>
                  
            <line class="bond" id="mol1bnd27" x1="132.258" x2="145.442" y1="64.186" y2="71.832"/>
                  
            <line class="bond" id="mol1bnd28" x1="145.442" x2="155.505" y1="71.832" y2="66.044"/>
                  
            <line class="bond" id="mol1bnd29" x1="158.669" x2="158.695" y1="60.38" y2="48.982"/>
                  
            <line class="bond" id="mol1bnd30" x1="158.695" x2="145.512" y1="48.982" y2="41.336"/>
                  
            <line class="bond" id="mol1bnd31" x1="135.448" x2="145.512" y1="47.124" y2="41.336"/>
                  
            <line class="bond" id="mol1bnd32" x1="161.812" x2="171.843" y1="66.058" y2="71.876"/>
                  
            <line class="bond" id="mol1bnd33" x1="79.471" x2="69.539" y1="64.074" y2="69.781"/>
                  
            <line class="bond" id="mol1bnd34" x1="66.25" x2="66.227" y1="75.589" y2="86.907"/>
                  
            <line class="bond" id="mol1bnd35" x1="66.227" x2="53.014" y1="86.907" y2="94.501"/>
                  
            <line class="bond" id="mol1bnd36" x1="24.138" x2="20.657" y1="17.385" y2="6.672"/>
                  
            <path class="atom" d="M18.367 36.011h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M27.307 23.616h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M54.943 51.251h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" id="mol1atm9" stroke="none"/>
                  
            <g class="atom" id="mol1atm11">
                        
                <path d="M68.252 28.391h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.608 4.055h.029q-.006 -.108 -.018 -.328q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" stroke="none"/>
                        
                <path d="M72.558 28.391h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M55.363 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM51.499 3.078q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M120.655 42.429q.0 .649 -.476 1.018q-.47 .363 -1.268 .363q-.417 -.0 -.768 -.065q-.345 -.06 -.577 -.173v-.589q.244 .113 .607 .202q.369 .089 .762 .089q.547 .0 .827 -.214q.28 -.214 .28 -.578q.0 -.238 -.107 -.398q-.101 -.167 -.351 -.31q-.25 -.143 -.697 -.298q-.625 -.226 -.946 -.553q-.316 -.334 -.316 -.899q.0 -.393 .196 -.667q.203 -.28 .554 -.429q.357 -.154 .816 -.154q.405 -.0 .738 .077q.339 .071 .613 .196l-.196 .53q-.25 -.113 -.548 -.184q-.298 -.078 -.625 -.078q-.459 .0 -.691 .197q-.232 .196 -.232 .518q.0 .244 .101 .411q.107 .166 .34 .297q.232 .125 .631 .28q.428 .155 .726 .339q.298 .179 .452 .435q.155 .25 .155 .637z" fill="#C6C62C" id="mol1atm20" stroke="none"/>
                  
            <path class="atom" d="M111.597 29.595q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.501 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM107.733 29.595q-.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm21" stroke="none"/>
                  
            <path class="atom" d="M131.189 29.634q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM127.325 29.634q.0 .922 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm22" stroke="none"/>
                  
            <path class="atom" d="M134.234 51.388h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.017 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" id="mol1atm23" stroke="none"/>
                  
            <path class="atom" d="M160.601 66.68h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.578v4.9z" id="mol1atm26" stroke="none"/>
                  
            <path class="atom" d="M68.517 71.664q-.0 .757 -.256 1.328q-.256 .566 -.756 .881q-.501 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.751 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM64.653 71.664q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm30" stroke="none"/>
                
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="19.012" x2="20.8965" y1="29.976" y2="27.363500000000002"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="22.781" x2="20.8965" y1="24.751" y2="27.363500000000002"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="28.638" x2="34.2665" y1="22.241" y2="24.091"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="49.851" x2="44.873000000000005" y1="46.969" y2="44.075"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="66.311" x2="66.311" y1="29.791" y2="35.486"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="66.311" x2="66.311" y1="29.791" y2="35.486"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="63.158" x2="58.1305" y1="24.122" y2="21.2215"/>
            <line class="hi" id="mol1bnd22" stroke="#C6C62C" x1="116.366" x2="111.1315" y1="42.869" y2="45.8775"/>
            <line class="hi" id="mol1bnd25" stroke="#C6C62C" x1="121.866" x2="125.50399999999999" y1="42.89" y2="45.0"/>
            <line class="hi" id="mol1bnd25" stroke="#3050F8" x1="129.142" x2="125.50399999999999" y1="47.11" y2="45.0"/>
            <line class="hi" id="mol1bnd26" stroke="#3050F8" x1="132.285" x2="132.2715" y1="52.788" y2="58.487"/>
            <line class="hi" id="mol1bnd28" stroke="#3050F8" x1="155.505" x2="150.4735" y1="66.044" y2="68.93799999999999"/>
            <line class="hi" id="mol1bnd29" stroke="#3050F8" x1="158.669" x2="158.68200000000002" y1="60.38" y2="54.681"/>
            <line class="hi" id="mol1bnd31" stroke="#3050F8" x1="135.448" x2="140.48000000000002" y1="47.124" y2="44.230000000000004"/>
            <line class="hi" id="mol1bnd32" stroke="#3050F8" x1="161.812" x2="166.8275" y1="66.058" y2="68.96700000000001"/>
            <line class="hi" id="mol1bnd33" stroke="#FF0D0D" x1="69.539" x2="74.505" y1="69.781" y2="66.92750000000001"/>
            <line class="hi" id="mol1bnd34" stroke="#FF0D0D" x1="66.25" x2="66.2385" y1="75.589" y2="81.24799999999999"/>
            <line class="hi" id="mol1bnd36" stroke="#3050F8" x1="24.138" x2="22.3975" y1="17.385" y2="12.028500000000001"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Phosphodiesterase 5 Inhibitors; Urological Agents; Vasodilator Agents","Title":"Sildenafil","UNII":"3M7OB98Y7H","Wikidata":"Q191521","Wikipedia":"Sildenafil","XLogP":1.5}